Clinical evidence from literature and mechanistic insights from bioinformatics both suggest a potential benefit of combination therapy in RPF. However, the evidence remains associative and exploratory. Further randomized controlled trials are warranted to evaluate the potential benefits and risks associated with the addition of immunosuppressants in patients with RPF.
Zheng et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: